ADMA Q4 2018 Earnings — ADMA Biologics, Inc. Revenue & Financial Results | Market Cap Arena

ADMAADMA Biologics, Inc.

$4B

Q4 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$4M-66.2% YoY

Gross Profit

-$7M-174.7% margin

Operating Income

-$17M-407.9% margin

Net Income

-$18M-444.7% margin

EPS (Diluted)

$-0.39

QoQ Revenue Growth

-4.1%

Cash Flow

Operating Cash Flow

-$19M

Free Cash Flow

-$20M

Stock-Based Comp.

$595,532

Balance Sheet

Total Assets

$89M

Total Liabilities

$69M

Stockholders' Equity

$20M

Cash & Equivalents

$23M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4M	$12M	-66.2%
Gross Profit	-$7M	$79,978	-8959.6%
Operating Income	-$17M	-$11M	-56.9%
Net Income	-$18M	-$13M	-38.9%